Cognition Therapeutics, Inc. - Common Stock (CGTX)
0.6540
-0.0260 (-3.82%)
NASDAQ · Last Trade: Jul 20th, 1:32 PM EDT
Detailed Quote
Previous Close
0.6800
Open
0.6900
Bid
0.6600
Ask
0.6650
Day's Range
0.6450 - 0.7075
52 Week Range
0.2223 - 2.535
Volume
3,144,046
Market Cap
40.53M
PE Ratio (TTM)
-0.8838
EPS (TTM)
-0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
18,621,662
Chart
About Cognition Therapeutics, Inc. - Common Stock (CGTX)
Cognition Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer’s disease and other forms of dementia. The company leverages its proprietary drug discovery platform to identify and advance small molecule therapeutics that target the underlying mechanisms of these conditions, aiming to improve cognitive function and enhance the quality of life for patients. By utilizing a unique approach that involves modulating cellular pathways associated with neurodegeneration, Cognition Therapeutics is dedicated to addressing significant unmet medical needs in the field of neurology. Read More
Power Metallic Mines Inc. (TSXV: PNPN | OTCQB: PNPNF) has launched a major Q2–Q3 2025 exploration push across its key Quebec polymetallic zones—Lion, Tiger, and Nisk. With three drill rigs currently operating and a fourth en route, the company is targeting over 20,000 meters of drilling this summer. The expanded program is backed by upgraded core logging facilities and an expanded field operations team.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Cognition Therapeutics Inc (NASDAQ: CGTX) continued to gain 12.10% in after-hours trading on Thursday, after a 20.82% surge during regular market hours.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
